Skip to content

Precigen PGEN Allowance for Doubtful Accounts

Allowance for Doubtful Accounts at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's allowance for doubtful accounts?
Precigen (PGEN) reported allowance for doubtful accounts of $0 in Q1 2026.
What is the long-term trend for Precigen's allowance for doubtful accounts?
Over 5 years (2020 to 2025), Precigen's allowance for doubtful accounts has grown at a -100.0% compound annual growth rate (CAGR), from $4.83M to $0.